Myo-inositol as a spectroscopic marker of neuroinflammation in frontotemporal lobar degeneration
- 1University of Cambridge, Department of Clinical Neurosciences; University of Cambridge, MRC Cognition and Brain Sciences Unit; Cambridge University Hospitals NH
Abstract
Background and ObjectivesCost-effective and mechanistically-informative biomarkers are needed to advance novel therapeutics for dementia. We focus on neuroinflammation in disorders associated with frontotemporal lobar degeneration (FTLD). Commonly used assays include positron emission tomography (PET) imaging and peripheral blood markers. However, PET is limited by radioactivity, which impedes repeated measurements, while peripheral markers are indirect measures of neuropathology. This study investigates the potential of proton magnetic resonance spectroscopy (MRS) - a non-invasive technique that can be deployed alongside structural imaging sequences - to quantify myo-inositol, an inflammatory metabolite found in astroglial and microglial cells. We test the following hypotheses (1) myo-inositol is elevated in brain regions affected by FTLD disorders; (2) myo-inositol in affected brain regions correlates with peripheral immune markers; and (3) myo-inositol in affected brain regions correlates with cognitive decline.
Methods54 people with FTLD-associated disorders (29 behavioural variant frontotemporal dementia, 25 progressive supranuclear palsy) and 73 age/sex-matched controls underwent single-voxel 7 Tesla MRS. 2cm isotropic voxels were placed over the right inferior frontal gyrus (R IFG, a disease-affected region of interest), and right occipital lobe (R OCC, a control region). Serum inflammatory markers were measured using nucleic acid-linked immuno-sandwich assays (NULISA). Cognition was assessed with the revised Addenbrookes Cognitive Examination (ACE-R). Mixed-effects and general linear models were used to evaluate diagnostic differences in regional myo-inositol and its association with cognition. Partial least squares regression identified two serum inflammatory components that covaried with myo-inositol; these components were subsequently tested in confounder-adjusted second-level linear models.
ResultsMyo-inositol was elevated in the R IFG ({beta} = 0.20, t = 5.10, p = 8.8 x 10^-7) but not in the R OCC ({beta} = 0.05, t = 1.36, p = 0.18), in people with FTLD versus controls. In FTLD, myo-inositol in the R IFG was positively associated with a peripheral inflammatory profile characterised by IL-6, IL-1{beta}, GFAP, CSF2, CRP, and CCL22 ({beta} = 0.39, t = 5.12, p = 3.60 x 10^-6). R IFG myo-inositol was negatively associated with ACE-R performance in patients ({beta} = -44.59, t = -4.12, p = 0.00016).
ConclusionMRS-derived myo-inositol is a promising neuroimaging biomarker of inflammation in FTLD. Elevated levels in disease-affected regions were associated with peripheral markers of inflammation (reflecting astrocytosis and microgliosis) and with cognitive impairment.
Related
- Association Between Postmortem Pathologic Burden and the Rate of Clinical Progression in Patients with Frontotemporal Lobar Degeneration
- Smartphone Passive Digital Phenotyping in Frontotemporal Lobar Degeneration
- Plasma immune signatures associate with neurodegeneration in frontotemporal lobar degeneration
- A Case Report Series on Supplementation with 1100 mg Myo-Inositol/ 300 mg D-Chiro-Inositol (3.6:1 Ratio), Antioxidants and Probiotics to Improve Oocyte Quality and Increase Pregnancy Chances in Women With History of ART Failures Without PCOS
- Volumetric Integrity of Frontotemporal and Perisylvian Regions for Predicting Behavioral and Language Impairment in Behavioral FTD: A Structural MRI Study
BibTeX
@misc{tan2026myoinositol,
title = {{Myo-inositol as a spectroscopic marker of neuroinflammation in frontotemporal lobar degeneration}},
author = {S. Y. Tan and M. Naessens and P. S. Jones and E. G. Todd and R. S. Williams and C. T. Rodgers and L. E. Hughes and N. L. Shapiro and J. Goddard and M. van Schaik and A. Heslegrave and H. Zetterberg and A. G. Murley and M. Malpetti and J. B. Rowe},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.18.26363386},
url = {https://www.medrxiv.org/content/10.64898/2026.09.18.26363386v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Myo-inositol as a spectroscopic marker of neuroinflammation in frontotemporal lobar degeneration
AU - S. Y. Tan
AU - M. Naessens
AU - P. S. Jones
AU - E. G. Todd
AU - R. S. Williams
AU - C. T. Rodgers
AU - L. E. Hughes
AU - N. L. Shapiro
AU - J. Goddard
AU - M. van Schaik
AU - A. Heslegrave
AU - H. Zetterberg
AU - A. G. Murley
AU - M. Malpetti
AU - J. B. Rowe
PY - 2026
DA - 2026/09/18
PB - medRxiv
DO - 10.64898/2026.09.18.26363386
UR - https://www.medrxiv.org/content/10.64898/2026.09.18.26363386v1
AB - Background and ObjectivesCost-effective and mechanistically-informative biomarkers are needed to advance novel therapeutics for dementia. We focus on neuroinflammation in disorders associated with frontotemporal lobar degeneration (FTLD). Commonly used assays include positron emission tomography (PET) imaging and peripheral blood markers. However, PET is limited by radioactivity, which impedes repeated measurements, while peripheral markers are indirect measures of neuropathology. This study investigates the potential of proton magnetic resonance spectroscopy (MRS) - a non-invasive technique that can be deployed alongside structural imaging sequences - to quantify myo-inositol, an inflammatory metabolite found in astroglial and microglial cells. We test the following hypotheses (1) myo-inositol is elevated in brain regions affected by FTLD disorders; (2) myo-inositol in affected brain regions correlates with peripheral immune markers; and (3) myo-inositol in affected brain regions correlates with cognitive decline. Methods54 people with FTLD-associated disorders (29 behavioural variant frontotemporal dementia, 25 progressive supranuclear palsy) and 73 age/sex-matched controls underwent single-voxel 7 Tesla MRS. 2cm isotropic voxels were placed over the right inferior frontal gyrus (R IFG, a disease-affected region of interest), and right occipital lobe (R OCC, a control region). Serum inflammatory markers were measured using nucleic acid-linked immuno-sandwich assays (NULISA). Cognition was assessed with the revised Addenbrookes Cognitive Examination (ACE-R). Mixed-effects and general linear models were used to evaluate diagnostic differences in regional myo-inositol and its association with cognition. Partial least squares regression identified two serum inflammatory components that covaried with myo-inositol; these components were subsequently tested in confounder-adjusted second-level linear models. ResultsMyo-inositol was elevated in the R IFG ({beta} = 0.20, t = 5.10, p = 8.8 x 10^-7) but not in the R OCC ({beta} = 0.05, t = 1.36, p = 0.18), in people with FTLD versus controls. In FTLD, myo-inositol in the R IFG was positively associated with a peripheral inflammatory profile characterised by IL-6, IL-1{beta}, GFAP, CSF2, CRP, and CCL22 ({beta} = 0.39, t = 5.12, p = 3.60 x 10^-6). R IFG myo-inositol was negatively associated with ACE-R performance in patients ({beta} = -44.59, t = -4.12, p = 0.00016). ConclusionMRS-derived myo-inositol is a promising neuroimaging biomarker of inflammation in FTLD. Elevated levels in disease-affected regions were associated with peripheral markers of inflammation (reflecting astrocytosis and microgliosis) and with cognitive impairment.
ER -